Press release
B-Cell Non-Hodgkin Lymphoma Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in B-Cell Non-Hodgkin Lymphoma Research. Learn more about our innovative pipeline today! @ B-Cell Non-Hodgkin Lymphoma Pipeline Outlook [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the B-Cell Non-Hodgkin Lymphoma Pipeline Report
* In July 2025, Hoffmann-La Roche announced a Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients.
* In July 2025, Novartis Pharmaceuticals announced a phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
* In July 2025, Regeneron Pharmaceuticals conducted a study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.
* In July 2025, Incyte Biosciences Japan GK organized a study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.
* DelveInsight's B-Cell Non-Hodgkin Lymphoma pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for B-Cell Non-Hodgkin Lymphoma treatment.
* The leading B-Cell Non-Hodgkin Lymphoma Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
* Promising B-Cell Non-Hodgkin Lymphoma Therapies such as Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.
Discover how the B-Cell Non-Hodgkin Lymphoma treatment paradigm is evolving. Access DelveInsight's in-depth B-Cell Non-Hodgkin Lymphoma Pipeline Analysis for a closer look at promising breakthroughs @ B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
B-Cell Non-Hodgkin Lymphoma Emerging Drugs Profile
* Valemetostat: Daiichi Sankyo
Valemetostat is an investigational and potential first-in-class EZH1/2 dual inhibitor in phase II clinical development for hematologic cancers including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and Non-Hodgkin lymphoma (NHL), including adult T-cell leukemia/lymphoma (ATL/L), peripheral T-cell lymphoma (PTCL), and B-cell lymphomas.
* MB-106: Mustang Bio
MB-106 is a CD20-targeted autologous CAR T cell therapy developed for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL). This therapy, optimized as a third-generation CAR derived from a fully human antibody, has shown promising results in clinical trials. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of B-cell non-Hodgkin lymphoma.
* CB-010: Caribou Biosciences
CB-010, our lead clinical-stage program, is an allogeneic anti-CD19 CAR-T cell therapy designed for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). It is the first known allogeneic CAR-T cell therapy in clinical trials to incorporate a PD-1 knockout, utilizing a genome-editing strategy aimed at enhancing antitumor activity by preventing premature CAR-T cell exhaustion. The manufacturing process for CB-010 involves three key edits using Cas9 chRDNA guides: knocking out the TRAC gene to remove the T cell receptor, site-specific insertion of an anti-CD19 CAR into the TRAC gene, and knocking out PD-1. Currently, the drug is in Phase I stage of its clinical trial for the treatment of r/r B-NHL.
* LP-284: Lantern Pharma
LP-284 is an innovative small molecule drug developed by Lantern Pharma, designed to selectively target cancer cells with mutations in DNA damage repair pathways. Its development is accelerated by AI and biological modeling through Lantern's RADR platform. The FDA has granted orphan drug designation to LP-284 for treating high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements. Currently, the drug is in Phase I stage of its clinical trial.
The B-Cell Non-Hodgkin Lymphoma pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of B-Cell Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Non-Hodgkin Lymphoma Treatment.
* B-Cell Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* B-Cell Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-Cell Non-Hodgkin Lymphoma market.
Get a detailed analysis of the latest innovations in the B-Cell Non-Hodgkin Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ B-Cell Non-Hodgkin Lymphoma Unmet Needs [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
B-Cell Non-Hodgkin Lymphoma Companies
Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
B-Cell Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
B-Cell Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming B-Cell Non-Hodgkin Lymphoma Therapies and key B-Cell Non-Hodgkin Lymphoma Developments @ B-Cell Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the B-Cell Non-Hodgkin Lymphoma Pipeline Report
* Coverage- Global
* B-Cell Non-Hodgkin Lymphoma Companies- Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Chia Tai Tianqing Pharmaceutical Group, Mustang Bio, Novartis, Loxo Oncology, Genmab, Nkarta, Nurix Therapeutics, Prelude Therapeutics and others.
* Promising B-Cell Non-Hodgkin Lymphoma Therapies - Bendamustine hydrochloride injection, ibrutinib, PF-3512676, Cyclophosphamide, Mitoxantrone, Vincristine, Velcade, Temsirolimus, Glofitamab, Atezolizumab, Obinutuzumab, and others.
* B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* B-Cell Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in B-Cell Non-Hodgkin Lymphoma drug development? Find out in DelveInsight's exclusive B-Cell Non-Hodgkin Lymphoma Pipeline Report-access it now! @ B-Cell Non-Hodgkin Lymphoma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* B-Cell Non-Hodgkin Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* B-Cell Non-Hodgkin Lymphoma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Valemetostat: Daiichi Sankyo
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CB-010: Caribou Biosciences
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* B-Cell Non-Hodgkin Lymphoma Key Companies
* B-Cell Non-Hodgkin Lymphoma Key Products
* B-Cell Non-Hodgkin Lymphoma- Unmet Needs
* B-Cell Non-Hodgkin Lymphoma- Market Drivers and Barriers
* B-Cell Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
* B-Cell Non-Hodgkin Lymphoma Analyst Views
* B-Cell Non-Hodgkin Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bcell-nonhodgkin-lymphoma-pipeline-appears-promising-with-75-leading-biotech-and-pharma-companies-driving-innovation-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-Cell Non-Hodgkin Lymphoma Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight here
News-ID: 4108812 • Views: …
More Releases from ABNewswire
Post-Construction Cleaning Demand Rises Among Miami Renovators as The Prime Clea …
Miami homeowners and contractors are driving increased demand for professional post-construction cleaning services, with The Prime Cleaner reporting significant growth in this specialty category across South Florida.
MIAMI, FL - Demand for professional post-construction cleaning services is rising across Miami as homeowners complete renovations and contractors seek reliable cleaning partners for new builds. The Prime Cleaner has expanded its post-construction cleaning services [https://www.theprimecleaner.com/service/post-construction-cleaning] to meet the growing need.
Miami's construction and renovation…
Extending the Invisible Cord: Why Bluetooth Repeaters Are Essential for Seamless …
We live in a wireless world. Our headphones, keyboards, speakers, and even our lightbulbs connect via Bluetooth, freeing us from the tangle of cables. Yet, despite its convenience, Bluetooth has a wellknown limitation: range. The connection between a device and its source-whether it's a phone streaming music or a sensor reporting data-can stretch only so far before it stutters and drops. For homes, offices, and industrial facilities, these dead zones…
Beyond GPS: How Bluetooth Beacons Are Bridging the Gap Between Digital and Physi …
In an era dominated by GPS, it is easy to assume we have solved the problem of location tracking. We can navigate bustling cities, track lost phones, and find the nearest coffee shop with pinpoint accuracy-provided we are outside. But the moment we step indoors, the satellite signals fade, leaving a blind spot in our connected experiences.
This is where a small, unassuming piece of technology is making a massive impact:…
ECI Jewelers Introduces Streamlined Selling Experience with Same-Day Offers and …
ECI Jewelers has enhanced its luxury watch and jewelry buying service with same-day market-based offers and instant payment options for sellers nationwide. The concierge-style approach includes free valuations, full insurance coverage during transit, and expert assessment from the company's New York City Diamond District location, simplifying the selling process for owners of premium timepieces from brands like Rolex, Patek Philippe, and Audemars Piguet.
Elegant Creations Inc, operating as ECI Jewelers, has…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
